Gilead Buys Myogen To Strengthen Pulmonology Franchise

The $2.5 bil. deal will add a late-stage candidate, ambrisentan, for the treatment of pulmonary arterial hypertension to Gilead's pipeline.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet